TIANFU-CHEM - Sorafenib tosylate CAS NO.475207-59-1

sorafenib tosylate basic information

indications and usage mechanisms of action clinical research adverse reactions

product name: sorafenib tosylate

synonyms: sorafenib tosylate;sorafenib & its intermediates;sorafinib mesylate;4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-n-(5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate;sorafenib tosylate(bay 43-9006,nexavar);2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-n-methyl-, 4-methylbenzenesulfonate;sorafenib tosylate (nexavar);sorafenib (nexavar)

cas: 475207-59-1

mf: c21h16clf3n4o3.c7h8so3

mw: 637.03

einecs:

product categories: bay 43-9006;inhibitors;mapk

mol file: mol file

sorafenib tosylate structure

sorafenib tosylate chemical properties

cas database reference 475207-59-1(cas database reference)

safety information

risk statements 36/37/38

safety statements 28-26

msds information

sorafenib tosylate usage and synthesis

indications and usage sorafenib tosylate is a new type of multi-target antitumor drug, was developed by the german bayer pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. sorafenib tosylate is mainly used in advanced liver cancer treatment and is well tolerated.

mechanisms of action sorafenib tosylate can simultaneously affect tumor cells and tumor blood vessels. it has a double antitumor effect: it can block the cell signal transduction pathways mediated by raf/mek/erk to directly inhibit tumor cell growth, while also inhibiting vegf and platelet derived growth factors (pdgf) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth.

clinical research in a stage three randomized clinical study of american and european treatments for advanced kidney cancer, 903 cases advanced kidney patients who had experienced one unsuccessful systematic treatment (biological immunity or chemotherapy) were randomly split into two groups. one group received sorafenib tosylate, while the other received a placebo. mid-term analysis found already 222 deaths and the objective efficacy of the two groups to be 10% and 2%, while 74% and 53% of patients had stabilized conditions. the sorafenib tosylate group’s survival period was longer than that of the placebo group, with the risk ratio as 0.72. however, this different does not have statistical significance, as this is only a mid-term analysis, and final analysis after treatment will yield the correct survival period comparison.

602 advanced liver cancer patients selected from the usa, europe, australia, and other countries and areas, who did not receive systematic treatment, were included in a study. results showed that compared to the placebo, taking sorafenib tosylate could extend their total survival period of patients with late stage or primary liver cancer by about 44% and their extend disease progression period by about 73%.

adverse reactions manageable diarrhea, rashes, fatigue, hand-foot syndrome, hypertension, alopecia, nausea, vomiting, and loss of appetite.

uses sorafenib tosylate (bay 43-9006, nexavar) is a small molecular inhibitor of vegfr, pdgfr, c-raf and b-raf with ic50s of 18 nm, 10 nm, 3 nm and 15 nm, respectively.

uses sorafenib tosylate (bay 43-9006) is a multikinase inhibitor of raf-1, b-raf and vegfr-2 with ic50 of 6 nm, 22 nm and 90 nm, respectively

uses an inhibitor of flk-1 (vegfr), pdgfr and raf kinases.

sorafenib tosylate preparation products and raw materials